Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,932 recruiting studies in this area right now.
By phase
- Not applicable2,031
- Phase 21,075
- Phase 1791
- Phase 1/Phase 2481
- Phase 3345
- Phase 4125
- Phase 2/Phase 384
Top conditions
- Multiple Myeloma328
- Acute Myeloid Leukemia279
- Lymphoma179
- Sickle Cell Disease134
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia96
- Follicular Lymphoma70
- Hematologic Malignancy67
- Hodgkin Lymphoma64
- Myelodysplastic Syndrome64
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm54
- Lymphedema49
- Acute Myeloid Leukemia (AML)48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center62
- City of Hope Medical Center58
- Mayo Clinic56
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital45
- Peking University People's Hospital43
Where studies are running
- California397
- Texas185
- Alabama157
- Maryland152
- Arizona127
- Massachusetts105
- Florida104
- New York96
- Ohio72
- Minnesota69
Recruiting studies4,932 total
- NCT02390752RecruitingPhase 1
Early drug study for children and young adults with hard-to-treat cancers
This Phase 1 trial tests pexidartinib (TURALIO) to see how safe it is and how well it works against refractory (hard-to-treat) leukemias and solid tumors, including tumors seen with NF1 and MPNST. It mainly helps researchers learn the best way to dose the medication and gather early signals of benefit.
Bethesda, MarylandAges 3–35 - NCT02399527Recruiting
Lymphatic problem registry for tracking outcomes
This study enrolls people with certain lymphatic (lymph fluid) conditions to collect information and track how they do over time. It may help doctors better understand outcomes and improve care.
Boston, MassachusettsAges Any age - NCT02422875Enrolling by invitation
Study of immune markers in autoimmune disease and lupus
This study looks at blood and immune cell markers (autoantibodies and immune cell “signatures”) to better understand autoimmune conditions, including lupus. It may help researchers identify which markers are linked to disease and how immune cells respond after vaccination.
Atlanta, GeorgiaAges 18 years+ - NCT02447874RecruitingPhase 1/Phase 2
Arginine treatment for children’s sickle cell pain
This early-phase study tests whether arginine can help control pain in children with sickle cell disease. You may be considered if your child is having a sickle cell pain episode that needs stronger pain medicine given through an IV.
Atlanta, GeorgiaAges 7–21 - NCT02254863RecruitingPhase 1
Stem cell transplant into the spinal fluid for rare brain diseases
This Phase 1 trial tests a transplant using special donated stem-cell–like cells placed into the spinal fluid to treat certain inherited brain diseases. It is mainly designed to check safety, and it may offer benefit by targeting brain and nerve damage.
Durham, North CarolinaAges 1 week–22 years - NCT02443831RecruitingPhase 1
CAR T-cell immunotherapy for high-risk childhood leukemia
This early-phase trial tests CAR T-cells made to attack leukemia cells with specific markers (CD19 and CD22). It may help people with difficult-to-treat, relapsed, or high-risk acute lymphoblastic leukemia (ALL), especially when standard treatments haven’t worked well.
LondonAges Up to 24 years - NCT02464696Recruiting
Noninvasive breathing support to avoid tube breathing in cancer
This trial studies a mask-based breathing treatment (noninvasive ventilation) for people with cancer and serious breathing trouble, to see if it can prevent the need for intubation (putting a breathing tube in). If you qualify, the goal is to help you breathe better without invasive airway support when possible.
Houston, TexasAges 18 years+ - NCT02432079Recruiting
Study genetics in heterotaxy and certain heart defects
This study looks at the genes behind heterotaxy and related congenital (from-birth) heart defects. You may be able to join if you have this condition—or if you are a close family member of someone who does.
Indianapolis, IndianaAges Any age - NCT02390635RecruitingPhase 1
Testing PET/MRI scans to find leukemia outside the bone marrow
This Phase 1 study uses special whole-body imaging scans (PET with CT, plus MRI) to look for signs of acute myeloid leukemia outside the bone marrow. It may help doctors better see where leukemia is and guide future care.
Houston, TexasAges 18 years+ - NCT02646839Enrolling by invitationPhase 2
Testing a gene-matched transplant approach for childhood leukemia
This trial studies a specific type of partially matched (haploidentical) stem cell transplant in children with ALL, AML, or MDS. It looks at whether using certain immune system gene patterns (KIR) and measuring leftover disease after treatment can improve outcomes and cost-effectiveness.
Los Angeles, CaliforniaAges Up to 21 years - NCT02560883Recruiting
Hairy cell leukemia patient data registry
This registry collects information about people with classic and variant hairy cell leukemia. It helps doctors learn from real-world patient data and may improve future care.
Miami, FloridaAges 18 years+ - NCT02438904Recruiting
Get help selecting stem cells after poor transplant recovery
This trial offers a specialized device to help choose certain stem cells after a transplant when graft function is poor or not working. It may help improve how well the transplant takes and functions in your body.
Houston, TexasAges Any age - NCT02203903RecruitingPhase 1
Donor T-cell treatment after transplant for high-risk AML and MDS
This Phase 1 trial studies an advanced form of donated immune cells given after a stem cell transplant to help prevent leukemia coming back. It mainly looks at safety and whether the treatment can work in people with very high-risk AML or MDS who have not relapsed.
Washington D.C., District of ColumbiaAges 6 months–80 years - NCT02333604Recruiting
Cancer experience registry for patients and caregivers
This registry collects information about the experiences of people with cancer and the people who care for them. Joining could help researchers better understand needs and improve support, without requiring cancer treatment changes.
Washington D.C., District of ColumbiaAges 18 years+ - NCT02633553Recruiting
Radiation after surgery for stage II or III thymoma
This trial looks at adding radiation after a complete surgery to remove a thymoma (a tumor from the thymus) at stages II or III. It may help lower the chance the cancer comes back by treating leftover microscopic disease after surgery.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT02269592Recruiting
Study blood marker changes in early, symptom-free blood cancers
This study follows people with early, “precursor” blood conditions to learn what changes in their blood or bone marrow signal progression. It may help doctors better predict outcomes and understand why some people develop symptom-causing cancer.
Boston, MassachusettsAges 18 years+ - NCT02207894Recruiting
Survey of removing inhibitors in hemophilia A treatment
This study collects real-world information on how well a personalized clotting-factor plan helps people with hemophilia A get rid of inhibitors. It may help doctors refine treatment for patients who develop antibodies that block factor therapy.
Frankfurt am Main, HesseAges Any age - NCT02595255Recruiting
Testing a hormone marker to predict infertility risk after childhood cancer
This study looks at whether a blood test (a hormone marker) can predict a child’s future risk of infertility after cancer treatment. If it works, it could help families and doctors plan earlier fertility and puberty-related care.
Montegnée, LiègeAges 3–14 - NCT02534649Recruiting
Drug-matching trial for adults with cancer DNA changes
This trial looks for the specific DNA or tumor changes in your cancer and then matches you to a targeted drug plan. It’s meant for people with early cancer that has not already been treated in this study.
BayonneAges 18 years+ - NCT02457962Recruiting
Registry study of outcomes from Mayo radiation treatments
This study collects information about how patients do after radiation treatment and stores some biological samples for future research. It includes people treated at Mayo Clinic Rochester for a cancer-focused (curative) course of radiation.
Rochester, MinnesotaAges Any age - NCT02356653RecruitingEarly Phase 1
Stem cell transplant help for children lacking a matching sibling
This expanded-access study offers a specific type of stem cell transplant preparation that removes certain immune cells (CD3 and CD19) from donor stem cells. It is for children who need a transplant but do not have a fully matched sibling donor and whose team cannot use the hospital’s usual matching device protocol.
Philadelphia, PennsylvaniaAges Up to 30 years - NCT02416388RecruitingPhase 2/Phase 3
Trial for AML treatments and preventing graft-versus-host disease
This trial tests different chemotherapy induction, consolidation (follow-up treatment), and strategies to prevent complications after an allogeneic stem cell transplant. It aims to improve overall survival and reduce serious transplant side effects like graft-versus-host disease (GVHD).
AmiensAges 18–61 - NCT02343042RecruitingPhase 1/Phase 2
Selinexor with standard therapies for multiple myeloma
This trial tests a new drug called selinexor (KPT-330) combined with various standard treatments for patients whose multiple myeloma has come back or stopped responding to therapy. The goal is to see if adding selinexor helps control the cancer better than current options, and to find the safest dose for different drug pairings.
Gilbert, ArizonaAges 18 years+ - NCT02445222RecruitingPhase 3
Follow-up study for people treated with CAR-T therapy
This study checks how people do over the long term after receiving CAR-T, an advanced immune treatment. It may help doctors understand long-term safety and benefits, and what to expect after treatment.
Phoenix, ArizonaAges birth–100 years
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,932 recruiting hematology studies from the U.S. registry right now, out of 7,407 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.